AI-generated summary
The authors report a prospective case series of 10 patients with lichen planus pigmentosus or pigmentary demarcation lines and skin of color, treated with a 755-nm PicoSure laser over 16 weeks. They describe significant pigmentation improvement, high patient satisfaction and minimal post-inflammatory hyperpigmentation, while noting that larger studies are needed to confirm long-term efficacy.
- Participants
- 10
- Who or what was studied
- Patients with lichen planus pigmentosus or pigmentary demarcation lines and Fitzpatrick skin types III-V
- Wavelengths
- 755 nm
- Limits stated in the abstract
- The study was a small prospective case series of 10 patients without a control group, and the authors state that larger studies with long-term follow-up are needed.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Background
Lichen Planus Pigmentosus (LPP) and Pigmentary Demarcation Lines (PDL) are common pigmentary disorders among individuals with skin of color (SoC), presenting challenges for treatment due to risks of side effects, such as post-inflammatory hyperpigmentation (PIH). PicoSure laser, a 755-nm picosecond laser, has shown promise in treating pigmentary conditions with minimal adverse effects.
Aims
To evaluate the safety and efficacy of PicoSure laser treatment in patients with LPP and PDL, focusing on pigmentation reduction, patient satisfaction, and adverse effects.
Patients/Methods
A prospective case series was conducted over 16 weeks, involving 10 patients (5 LPP, 5 PDL) with Fitzpatrick skin types III-V. Patients underwent PicoSure laser treatment using a 755-nm wavelength, with assessments based on pigmentation reduction, patient satisfaction (via a visual analogue scale), and adverse effects.
Results
All patients demonstrated significant improvement in pigmentation. In LPP cases, 4 patients achieved > 90% improvement (Grade V), while 1 patient showed > 75% (Grade IV) improvement. PDL patients had > 75% (Grade IV) improvement in the majority of the cases. No significant adverse effects were reported, with minimal PIH observed. High patient satisfaction was reported across all cases.
Conclusions
PicoSure laser offers a safe and effective treatment for LPP and PDL in patients with skin of color, providing significant pigmentation reduction with minimal risk of PIH. It serves as a promising treatment alternative to traditional lasers, with potential for broader application in this demographic. Further studies with larger sample sizes are warranted to confirm long-term efficacy.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Laser, GRADE, Visual analogue scale, Wavelength. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.